CyanoCapture and Persist AI Partner to Build World's First Robotic GMP Facility for Oral Protein and Peptide Drugs
核心洞察
CyanoCapture (搜索) and Persist AI (搜索) announced a strategic collaboration to build a next-generation GMP manufacturing facility in the San Francisco Bay Area, expected to be operational by Q4 2026.
The facility will be the first of its kind to combine cyanobacteria (搜索) culture and processing with robotic automation for clinical-scale production of novel oral protein (搜索) and peptide therapeutics.
The partnership addresses the pharmaceutical industry's challenge of delivering proteins and peptides orally rather than through injection, potentially eliminating daily injections for millions of patients.
CyanoCapture (搜索), the innovator in cyanobacteria (搜索)-based oral drug delivery, and Persist AI (搜索), the leader in AI-driven robotic pharmaceutical formulation, announced a strategic collaboration to jointly build a next-generation GMP manufacturing facility in the San Francisco Bay Area. The facility, expected to be operational by Q4 2026, will be the first of its kind to combine cyanobacteria culture and processing with robotic automation for clinical-scale production of novel oral protein (搜索) and peptide therapeutics.
Revolutionary Approach to Oral Biologics Delivery
The collaboration addresses one of the pharmaceutical industry's most persistent challenges: delivering proteins and peptides orally rather than through injection. CyanoCapture (搜索)'s proprietary platform uses the world's fastest-growing cyanobacterial cell line and protein (搜索) nanocages called carboxysomes (搜索) to encase and deliver biologics (搜索), potentially eliminating the need for daily injections that burden millions of patients worldwide.
Cyanobacteria (搜索), such as spirulina, are naturally rich in bioactive compounds, peptides and antioxidants. CyanoCapture (搜索) rewrites the DNA of these fast-growing photosynthetic cells, making it possible to programme these cells into producing large amounts of popular peptides and therapeutic molecules, according to the user's design.
"Our vision is to turn the world's most powerful photosynthetic cell into a platform for scalable drug production that could one day be in every city. Partnering with Persist AI (搜索) gives us the robotic precision and AI-driven optimization needed to bring oral biologics (搜索) from the lab to patients faster than ever before," said David Kim, CEO of CyanoCapture (搜索).
AI-Driven Manufacturing Innovation
The joint GMP facility will leverage Persist AI (搜索)'s robotic systems for formulation development, clinical trial material production, and analytical testing. AI will orchestrate scheduling, workflow tracking, and process optimization throughout the manufacturing pipeline. This represents the first robotic facility designed specifically for cyanobacteria (搜索) culture, processing, and encapsulation at clinical scale.
Persist AI (搜索)'s robotic Cloud Lab already develops formulations 30 times faster than traditional methods. "This partnership represents a convergence of two transformative technologies. By combining this with CyanoCapture (搜索)'s breakthrough oral delivery platform, we're not just accelerating drug development, we're reimagining how biologics (搜索) can be manufactured and delivered to patients who deserve better options than needles," said Karthik Raman, CEO of Persist AI.
Clinical Applications and Future Impact
The facility will produce clinical trial materials for multiple therapeutic programs, with initial focus on converting injectable biologics (搜索) into oral formulations. Early research and process development will be enhanced by machine learning models trained on Persist AI (搜索)'s extensive formulation datasets.
Ben Stein, General Partner at Cartography Ventures (搜索), emphasized the significance of the partnership: "This partnership between CyanoCapture (搜索) and Persist AI (搜索) exemplifies bringing together two transformative founders and technologies to create an entirely new category of oral biologics (搜索) manufacturing. The potential to produce these therapies at clinical scale, with AI-driven robotics that ensures speed and precision, is a breakthrough that patients and pharma partners have been waiting for."
The collaboration represents a convergence of photosynthetic biomanufacturing and AI-driven robotics, potentially transforming how life-saving biologics (搜索) reach patients by offering oral alternatives to injectable therapies.